A Preliminary Clinical Study of Ct1341—a Steroid Anaesthetic Agent

Abstract

The effects of a new steroid anaesthetic agent (CT1341) were studied in twenty volunteers divided into three groups. In group I, serial measurements were made of heart rate, blood pressure and respiratory rate. In group II, detailed haemodynamic studies were made in patients undergoing diagnostic cardiovascular investigations. These studies included measurement of cardiac output, stroke volume and arterial blood gases. In group HI, time from induction to "true recovery" was measured following a single intravenous injection of the drug. This agent produced a stable anaesthetic state in all cases. Anaesthesia was characterized by a rise in respiratory rate and pulse rate with a slight fall in systolic and diastolic blood pressure. A significant fall in Pa<>, occurred in those patients breathing air. The mean recovery time in six patients was 24.3 min. CT1341 produced safe and stable anaesthesia in all twenty cases and is worthy of further clinical trial. • CT1341 is manufactured by Glaxo Laboratories Limited, Greenford, Middlesex. 3a-hydroxy-5a-pregnane-ll,20 dione 0.9% w/v 21-acetoxy-3a-hydroxy-5o pregnane-11,20 dione 0.3% w/v Cremophor EL 20% w/v Sodium chloride 0.25% w/v Water for injection BP to 100% Throughout this paper the dosage of CT1341 will be expessed as ml of the above formulation. This paper reports the findings of a preliminary and limited clinical investigation conducted with the approval of the Committee on Safety of Drugs.

Anaesthetic, cardiovascular and respiratory effects of a new steroidal agent CT 1341: a comparison with other intravenous anaesthetic drugs in the unrestrained cat

“…It is a potent intravenous anaesthetic in animals, which produces rapid induction of anaesthesia without vascular irritation. The initial trials of CT 1341 in man (Campbell, Forrester, Miller, Hutton, Kennedy, Lawrie, Lorimer & McCall, 1971;Savege, Foley, Coultas, Walton, Strunin, Simpson & Scott, 1971;Clarke, Montgomery, Dundee & Bovill, 1971;Swerdlow, Chakraborty & Zahangir, 1971) appear to substantiate the findings in animals.…”

The Effect of CT 1341, a New Steroid Anesthetic, on the Isolated Heart Muscle

“…The injection is formulated as follows: Preliminary studies have indicated that CT 1341 is a promising intravenous anesthetic agent characterized by immediate induction of anesthesia of short duration, and rapid and uncomplicated recovery from anesthesia (Child et al 1971;Campbell et al 1971;Clarke et al 1971;Savege et al 1971;Swerdlow et al 1971). In regard to cardiovascular effects, Campbell et al (1971) reported a slight fall in blood pressure and stroke volume and a significant rise in heart rate with minimal changes in cardiac output. Savege et al (1971) also reported a well-sustained cardiac output associated with a considerable fall in systolic blood pressure and increase in heart rate.…”

Eltanolone for induction of anaesthesia and to supplement nitrous oxide for minor gynaecological surgery

“…Minaxolone was also water soluble. Early clinical studies showed that recovery was relatively slow [3,4], but it was withdrawn prior to release as the result of toxicological studies in animals.Althesin (alphaxolone/alphadolone) approached the ideal intravenous anaesthetic, with acceptable cardiorespiratory effects and rapid recovery [5]. Its pharmacokinetic properties allowed its use by continuous infusion and it was the first intravenous anaesthetic that could be used as the hypnotic component of total intravenous anaesthesia [6] and for sedation in the intensive care unit [7] and yet allow acceptable rates of recovery.…”